Cargando…
Delabelling multiple antibiotic allergy: Practical issues
With the growing incidence of multi-drug resistant organisms, delabelling incorrect antibiotic allergies has become an integral part of antimicrobial stewardship worldwide. For example, around 90% of penicillin allergy labels are found to be inaccurate following a full allergy work-up, which deprive...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061016/ https://www.ncbi.nlm.nih.gov/pubmed/37007647 http://dx.doi.org/10.3389/falgy.2023.1156137 |
_version_ | 1785017207993925632 |
---|---|
author | Li, Philip Hei Thong, Bernard Yu-Hor |
author_facet | Li, Philip Hei Thong, Bernard Yu-Hor |
author_sort | Li, Philip Hei |
collection | PubMed |
description | With the growing incidence of multi-drug resistant organisms, delabelling incorrect antibiotic allergies has become an integral part of antimicrobial stewardship worldwide. For example, around 90% of penicillin allergy labels are found to be inaccurate following a full allergy work-up, which deprive patients the use of effective first-line penicillin antibiotics and increase the risk of antimicrobial resistance with the use of other extended spectrum non-penicillin antimicrobials. Significant numbers of adult and paediatric patients over time are labelled with multiple penicillin and non-penicillin antibiotic allergies often during inappropriate antimicrobial use, resulting in a label of “multiple antibiotic allergy”. In contrast to delabelling penicillin allergy where oral direct provocation tests can be used for low-risk, mild reactions, and sensitivity/specificity/positive and negative predictive values of skin tests have been demonstrated, diagnostic tests for multiple antibiotic allergy often require the use of a combination of in-vivo and in-vitro tests across different antimicrobial classes for evaluation. Shared decision making with patients and informed consent are also needed when prioritising which drugs to delabel first, balancing the risks, benefits of testing vs. interim use of alternative antibiotics. Similar to delabelling penicillin allergy, the cost-effectiveness of delabelling multiple drug allergies is unknown. |
format | Online Article Text |
id | pubmed-10061016 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100610162023-03-31 Delabelling multiple antibiotic allergy: Practical issues Li, Philip Hei Thong, Bernard Yu-Hor Front Allergy Allergy With the growing incidence of multi-drug resistant organisms, delabelling incorrect antibiotic allergies has become an integral part of antimicrobial stewardship worldwide. For example, around 90% of penicillin allergy labels are found to be inaccurate following a full allergy work-up, which deprive patients the use of effective first-line penicillin antibiotics and increase the risk of antimicrobial resistance with the use of other extended spectrum non-penicillin antimicrobials. Significant numbers of adult and paediatric patients over time are labelled with multiple penicillin and non-penicillin antibiotic allergies often during inappropriate antimicrobial use, resulting in a label of “multiple antibiotic allergy”. In contrast to delabelling penicillin allergy where oral direct provocation tests can be used for low-risk, mild reactions, and sensitivity/specificity/positive and negative predictive values of skin tests have been demonstrated, diagnostic tests for multiple antibiotic allergy often require the use of a combination of in-vivo and in-vitro tests across different antimicrobial classes for evaluation. Shared decision making with patients and informed consent are also needed when prioritising which drugs to delabel first, balancing the risks, benefits of testing vs. interim use of alternative antibiotics. Similar to delabelling penicillin allergy, the cost-effectiveness of delabelling multiple drug allergies is unknown. Frontiers Media S.A. 2023-03-16 /pmc/articles/PMC10061016/ /pubmed/37007647 http://dx.doi.org/10.3389/falgy.2023.1156137 Text en © 2023 Li and Thong. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Allergy Li, Philip Hei Thong, Bernard Yu-Hor Delabelling multiple antibiotic allergy: Practical issues |
title | Delabelling multiple antibiotic allergy: Practical issues |
title_full | Delabelling multiple antibiotic allergy: Practical issues |
title_fullStr | Delabelling multiple antibiotic allergy: Practical issues |
title_full_unstemmed | Delabelling multiple antibiotic allergy: Practical issues |
title_short | Delabelling multiple antibiotic allergy: Practical issues |
title_sort | delabelling multiple antibiotic allergy: practical issues |
topic | Allergy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061016/ https://www.ncbi.nlm.nih.gov/pubmed/37007647 http://dx.doi.org/10.3389/falgy.2023.1156137 |
work_keys_str_mv | AT liphiliphei delabellingmultipleantibioticallergypracticalissues AT thongbernardyuhor delabellingmultipleantibioticallergypracticalissues |